Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Gilead Sciences, Inc. (GILD) Q3 2025 Earnings Call Transcript
08:56pm, Thursday, 30'th Oct 2025
Gilead Sciences, Inc. ( GILD ) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Jacquie Ross - Senior Vice President of Treasury and Investor Relations Daniel O'Day - Chairman &
Gilead (GILD) Reports Q3 Earnings: What Key Metrics Have to Say
07:31pm, Thursday, 30'th Oct 2025
Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Stre
Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates
06:16pm, Thursday, 30'th Oct 2025
Gilead Sciences (GILD) came out with quarterly earnings of $2.47 per share, beating the Zacks Consensus Estimate of $2.15 per share. This compares to earnings of $2.02 per share a year ago.
Gilead posts higher profit as HIV sales rise, helped by prevention drugs
04:05pm, Thursday, 30'th Oct 2025
Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for its new prevention drug Yeztugo, helping to boost its profit above Wall Stree
Gilead Sciences Announces Third Quarter 2025 Financial Results
04:02pm, Thursday, 30'th Oct 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2025 results of operations. “We continue to deliver on Gilead's robust portfo
Victory! AHF, 100 Organizations Kill Gilead's Greedy Drug Price Hikes
04:11pm, Wednesday, 29'th Oct 2025
WASHINGTON--(BUSINESS WIRE)--Victory! AHF, 100 Organizations Kill Gilead's Greedy Drug Price Hikes.
Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?
10:02am, Wednesday, 29'th Oct 2025
Gilead Sciences gears up for Q3 results with strong HIV gains and new FDA approvals, amid challenges in its Cell Therapy business.
Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings
10:40am, Tuesday, 28'th Oct 2025
Eli Lilly, Merck, Gilead, Bristol Myers Squibb and AbbVie, among other pharmaceutical companies, are slated to report third-quarter earnings this week.
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
12:06pm, Monday, 27'th Oct 2025
As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.
Curious about Gilead (GILD) Q3 Performance? Explore Wall Street Estimates for Key Metrics
10:16am, Monday, 27'th Oct 2025
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quar
Pharmaceutical Stocks To Watch Now – October 24th
02:40am, Sunday, 26'th Oct 2025
Eli Lilly and Company, Wellgistics Health, Pfizer, AbbVie, and Gilead Sciences are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks a
What To Expect From Gilead In Q3 2025
10:56am, Friday, 24'th Oct 2025
Here we are approaching an important event, namely October 30, when Gilead will announce its results for the third quarter of 2025. Since my last article, its stock price has hit new 52-week highs. On
Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?
11:00am, Thursday, 23'rd Oct 2025
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present new research that reinforces its commitment to advancing innovation for people living with liver disease at The
Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know
07:01pm, Wednesday, 22'nd Oct 2025
Gilead Sciences (GILD) concluded the recent trading session at $121.46, signifying a -2.11% move from its prior day's close.
